Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Genvoya

02 5Prezista/Prezcobix/Rezolsta/Symtuza

03 2Revenue share - Symtuza

04 10Stribild

05 3Symtuza

PharmaCompass

01

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
SCOPE Summit
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
SCOPE Summit
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 2,184

2019 Revenue in Millions : 2,110

Growth (%) : 4

blank

02

arrow
SCOPE Summit
Not Confirmed

03

arrow
SCOPE Summit
Not Confirmed

04

arrow
SCOPE Summit
Not Confirmed

05

arrow
SCOPE Summit
Not Confirmed

06

arrow
SCOPE Summit
Not Confirmed

07

arrow
SCOPE Summit
Not Confirmed

08

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
SCOPE Summit
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
SCOPE Summit
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 2,083

2020 Revenue in Millions : 2,184

Growth (%) : -5

blank

09

arrow
SCOPE Summit
Not Confirmed

10

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
SCOPE Summit
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
SCOPE Summit
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 1,943

2021 Revenue in Millions : 2,083

Growth (%) : -7

blank